Revised on 2/28/2024
This chapter focuses on the IRB submission and review processes. It includes an overview of iStar, the electronic application system used to submit all human subjects proposals to the IRB, the criteria for IRB approval, the review process for the different submission types, and IRB determinations and correspondence details.
The IRB Submission Tracking and Review (iStar) online system supports all applications: new study, continuing review, amendment, and reportable event. Access to the iStar system is granted according research roles and oversight responsibilities.
The application guides users to questions specific to the nature of their research and ensures that information required for regulatory purposes is appropriately collected. For example, if a protocol includes minor subjects, users are required to select a child risk category and explain the process for obtaining assent and parental permission.
iStar maintains the currently approved study. With each amendment submission, the investigator is required to update the previously approved study to reflect the changes under review. iStar systematically records all changes and stores previous versions of the application and study documents in an accessible manner.
Among the documents available in iStar are:
- IRB submission (initial and continuing review)
- Informed consent and assent forms (if applicable, these documents are available in both approved and draft form)
- Scientific protocol
- Study grant
- Recruitment material
- Surveys and questionnaires
- Approval documents from collaborating Institutions
- Ancillary committee approvals
- Reportable events and reports
- IRB and study team correspondence
- IRB approval notices
- Other documents related to IRB review
In addition to being a submission and document storage system, iStar creates historical records and provides audit trails of the IRB review process. All study-specific correspondence between the research team and the IRB are created and stored in iStar.
ClinicalTrials.gov is a database of both publicly and privately supported clinical studies that are conducted for participants around the world, located at the National Library of Medicine.
On September 16th, 2016, The U.S. Department of Health and Human Services expanded requirements for registration and results information to clinicaltrials.gov for FDA- regulated drug, biological, and device products. Simultaneously, NIH issued a policy requiring registration and results information to clinicaltrials.gov for all NIH-sponsored clinical trials, regardless of whether the trial is covered by the HHS Final Rule.
Registration and results reporting are required for applicable clinical trials; however, ClinicalTrials.gov allows voluntary reporting of other studies that:
- Are in conformance with any applicable human subject or ethics review regulations (or equivalent) and
- Are in conformance with any applicable regulations of the national (or regional) health authority (or equivalent) Investigators may choose to register a study that is not an applicable clinical trial as a condition to publish study results in a journal. FDA regulations require reporting of results from registered trials.
The Responsible Party must generally report results no later than 12 months after the trial completion date. Results must include participant baseline characteristics, participant flow diagram, outcomes, and adverse events. Instructions for submitting results are available at ClinicalTrials.gov. FDA also requires sponsors or investigators to certify compliance with ClinicalTrials.gov registration when submitting certain applications to the FDA. Form FDA 3674 is used to certify compliance.”
The text above may be used in NIH applications requiring a statement of USC policy.
Registration is required by law per Section 801 of the Food and Drug Administration Amendments Act and the Final Rule for Clinical Trials Registration and Results Information Submission (September 2016) for:
- FDA Clinical Trials defined as intervention studies that include drugs, biological products, and medical devices;
- NIH Clinical Trials defined as biomedical and behavioral studies of human subjects;
- Publication of research studies that assigns human subjects to health-related interventions and evaluates their outcomes. Other public registries are also available to meet criteria for ICMJE and WHO; and
- Reimbursement of Medicare claims for items and services in clinical trials that are qualified for coverage.
Registration of an applicable clinical trial must be submitted no later than 21 days after enrollment of the first participant.
Non-compliance of these requirements may result in civil monetary penalties, withholding/recovery of federal funds, and/or withholding of publications.
Principal Investigators are responsible to register their studies prior to participant enrollment in the Protocol Registration System (PRS) of ClinicalTrials.gov.
For additional information refer to USC Guidance for Registering at ClinicalTrials.gov.
See also: Section 9.10 – Posting the Clinical Trial Informed Consent Form
Review of Scientific Merit
Scientific merit is a basic expectation of human subject research and is an integral part of the IRB review. It is not ethical to expose subjects to risk and inconvenience if the research has no merit. The IRB takes into consideration any scientific review conducted by other committees or outside entities before the study was submitted to the IRB. Non-cancer, investigator-initiated clinical trials that had no prior scientific review are forwarded to the scientific review committee of the Clinical Translational Sciences Institute (CTSI). The IRB process will continue once the committee review is complete.
Federal regulations (45 CFR 46) as well as the Association for the Accreditation of Human Research Protection Programs (AAHRPP) require the IRB to review the scientific merit of proposals.
Peer or scientific review by USC institutional scientific committees such as the Cancer Center Clinical Investigations Committee, the Clinical Trials Unit (CTU), reviews by committees external to USC such as NIH cooperative groups, NIH study sections, sponsor review committee(s), and regulatory agencies such as the Food and Drug Administration provide assurance that experts have evaluated the study and found it meritorious. At HSC, for protocols that have not undergone peer/scientific review, additional reviewers with knowledge in the relevant discipline may be assigned to provide confidence in the scientific merit of the study.
The IRB reviews all studies to ensure that:
- The research uses procedures consistent with sound research design
- The research design will allow the proposed research questions to be answered
- The risk/benefit relationship is acceptable
- The purpose and specific aims are clear and feasible, and the research will contribute to generalizable knowledge
The IRB may request for an expert consultant to review a proposed research project or defer to scientific review committees in order to determine whether a study has sufficient scientific value (merit) and/or if a study design places subjects at unnecessary risk. Before the consultant reviews the study, the IRB office will confirm with the consultant(s) that there is no potential conflict of interest.
Student research is expected to be reviewed by a dissertation committee for scientific validity. Projects that do not provide an actual benefit to society or have compelling scientific merit can still be approved by the IRB if all other approval criteria are met.
For Department of Defense sponsored research, review of scientific merit is required prior to initial IRB approval. In addition, any substantive amendment to approved research sponsored by DOD must undergo scientific review prior to the review by the convened IRB.
In order to approve research, federal regulations (45 CFR 46.111) require that the IRB (reviewer or Full Board) determine that all of the following requirements are satisfied:
- Risks to subjects are minimized: (a) By using procedures that are consistent with sound research design and that do not unnecessarily expose subjects to risk, and (b) Whenever appropriate, by using procedures already being performed on the subjects for diagnostic or treatment purposes.
- Risks to subjects are reasonable in relation to anticipated benefits, if any, to subjects, and the importance of the knowledge that may reasonably be expected to result. In evaluating risks and benefits, the IRB will consider only those risks and benefits that may result from the research (as distinguished from risks and benefits of therapies subjects would receive even if not participating in the research). The IRB will not consider possible long-range effects of applying knowledge gained in the research (e.g. the possible effects of the research on public policy) as among those research risks that fall within the purview of its responsibility.
- Selection of subjects is equitable. In making this assessment the IRB must take into account the purpose(s) of the research and the setting in which the research will be conducted and must be particularly cognizant of the special problems of research that involves a category of subjects who are vulnerable to coercion or undue influence, such as children, prisoners, individuals with impaired decision- making capacity, or economically or educationally disadvantaged persons.
- Informed consent will be sought from each prospective subject or the subject’s legally authorized representative, in accordance with, and to the extent required by 45 CFR 46.116.
- Informed consent will be appropriately documented, or appropriately waived in accordance with 45 CFR 46.117.
- When appropriate, the research plan makes adequate provision for monitoring the data collected to ensure the safety of subjects.
- When appropriate, there are adequate provisions to protect the privacy of subjects and to maintain the confidentiality of data.
- When some or all of the subjects are likely to be vulnerable to coercion or undue influence, such as children, prisoners, individuals with impaired decision-making capacity, or economically or educationally disadvantaged persons, the IRB will ensure additional safeguards have been included in the study to protect the rights and welfare of these subjects. Refer to Chapter 13 – Vulnerable Subject Populations.
In addition to these regulations, the IRB must also consider:
- PI/study team qualifications, including credentialing and hospital privileges
- Adequacy of research description and methodology
- Certification that all study personnel have completed required training
- Conflict of Interest (PI and study staff)
- Subject recruitment
- Privacy and confidentiality
- Risk/benefit ratio
- HIPAA applicability and waivers
- Scientific merit
- Budget review
- California laws and university policies
The IRB evaluates the responses provided in all corresponding subject sections of the iStar submission application to determine that the study will be conducted in accordance with applicable regulations and requirements.
Review of Research Funds/Budget
Assurance of adequate financial resources for proposed research is inherent in the IRB’s responsibilities and obligations in the protection of human subjects. Subjects may be put at risk if the protocol cannot be carried out as approved, due to inadequate resources. In most cased the IRB will rely on access to budget information through the Kuali Coeus system for review. When a study on HSC is not funded by an external sponsor, the department/school representative must attest that all study costs are guaranteed. The department chair has the option of assigning budget approval to either the division level or department level representative.
The IRB will not approve a study when requests for documentation of funding information are not satisfied. For social behavioral research, no department approval is required, except in exceptional cases, and in the Ostrow School and Pharmacy School, where single level approval is required.
Grants and Contracts Only Submissions
Grant and Contract (CG) Only submissions are projects that lack definite plans for involvement of human subjects. When necessary to satisfy a funding sponsor, the Principal Investigator (PI) may submit a grant/contract application through iStar. The CG application is not approval to conduct human subjects research, it is an acknowledgement of the grant application.
The PI must generate and submit a new human subjects research application when the study protocol is complete. IRB approval is required for the human subjects application prior study initiation or any human subject involvement.
Grant and Contract Only Submissions include:
- Applications for approval of Center, Training or Program Project Grants, where the application outlines the administrative core requirements and does not include a plan for the involvement of human subjects.
- Applications requesting approval for development purposes only, under 45 CFR 46.118 and 119, where the proposals lack definite plans for the inclusion of human subjects.
The IRB will issue correspondence in iStar acknowledging the submission of the grant and stating the project does not have definite plans to involve human subjects. No human subjects may be involved in any project supported by these awards until the full protocol submission has been reviewed and approved by the IRB and certification submitted, by the institution, to the Federal department or agency component supporting the research.
To obtain an exempt determination, the investigator must submit an exempt iStar application.
At USC, designated staff and IRB members have the authority to approve exempt studies. Reviewers of exempt determinations conduct a review of the project to determine if it qualifies for exempt status according to IRB policy, human subjects research regulations, and ethical standards. To facilitate review, additional revisions may be requested. If the study does qualify, the PI is notified, and no further review is needed.
When the study does not meet exempt criteria, the IRB staff and/or designee determines the appropriate level of review, notifies the investigator, and guides the investigator with resubmission at the required level. If exempt determination is unclear, the Chair or designee may assist with the determination. Exempt determinations are distributed to all IRB members electronically and acknowledged by each committee.
All exempt research will be subject to USC Post Approval Monitoring process of Progress Updates. Progress Updates will be sent to all study team members two years after the initial approval of the study. Investigators will have two options at the time of receipt of the progress update: 1) to close the study (see section 8.3) or 2) fill out the progress update form and keep the study open for an additional two years when the process will be repeated.
IRB reviewers have access to all necessary application materials in the iStar system, including:
- A completed iStar application with conflict of interest statement
- Proposed information sheet(s) and/or scripts as appropriate
- Information Sheets
- Recruitment flyers
- Surveys, questionnaires, or videos
- Relevant grant applications
Amendments and Revisions to Exempt Research
Once a project is determined by the IRB to be exempt, all changes that affect risk must be resubmitted to the IRB via an amendment. In addition, any study personnel or funding changes must be submitted. Study personnel changes (with certain exceptions) can be made to the IRB application without submitting an amendment. To do this, research staff can select the “Edit Study Personnel” activity in the iStar study workspace and add or delete study personnel.The “Simple amendments” function within the iStar system must be submitted for additional funding added to the project or change of funding.
To submit a project for Full Board review, the investigator must submit a Full Board iStar application. The IRB staff reviews the application to ensure it is complete, and if necessary, will request revisions and/or clarifications from the investigator. The staff review is available to the IRB in iStar. The IRB staff schedules the study for the next available IRB meeting. The IRB Chair or IRB Associate Directors select primary and secondary (and tertiary when applicable) reviewers. The reviewers’ comments, questions, and contingencies are posted in the iStar system and discussed during the Full Board meeting. Study materials and reviewer comments are available to all committee members.
The Full Board review process is described below:
- A majority of the members of the IRB and at least one non-scientist and one non- affiliated member (can be the same member with dual roles) must be present.
- If the quorum is lost during a meeting no action may be taken until the quorum is restored.
- In order for a research project to be approved, it must receive the approval of a majority of the members present at the meeting.
- The IRB Chair reminds the IRB members of the requirement to disclose conflicting interests. The Chair polls the members present for any conflicting interests not previously declared or identified by IRB staff.
- IRB members cannot vote on a study if they are an investigator or member of the study team, if they significantly contributed to the design and conduct of the proposed study, if they meet the criteria for a financial conflict of interest, or if they have other interests that may affect their objectivity.
- A member with a potential conflicting interest may be invited to answer preliminary questions about a study, but then leave the meeting until the final vote is taken. The meeting minutes will record the name of any member who does not participate in the final vote on a study because of a conflicting interest.
- For studies involving subjects who may be vulnerable to coercion or undue influence, the IRB Chair, Director, or staff will ensure that one or more individuals who are knowledgeable about or have experience working with the subjects will review the study. These individuals may be current IRB members and/or consultants.
- For studies involving the recruitment of prisoners, the IRB Chair, Director, or Staff will ensure that a prisoner representative will be present at the meeting.
- A meeting may be conducted by conference call provided that each participating IRB member has received all pertinent material prior to the meeting and can actively and equally participate in the discussion of all protocols. Meeting minutes must clearly document that these two conditions have been satisfied and should specify which members were present via conference call.
- IRB meetings are scheduled at regular intervals appropriate to the amount of research requiring review and with sufficient frequency to ensure that the IRB can adequately oversee the progress of the research it has previously approved.
- Each protocol undergoing initial review, continuing review, or amendment will be discussed and voted upon separately.
Full Board Reviewer Assignments
The IRB uses a “primary reviewer” system for review of all new research proposals at its convened meeting. Members will be assigned studies for which they will be responsible. Reviewer assignments are made with the following goals in mind: to ensure review by a member with appropriate expertise and to equally distribute assignments. The expectation is that each IRB member will be familiar with every study on a meeting agenda.
The number of assigned reviewers differs according to the nature of the submission and whether previous peer review(s) for scientific merit is available (such as review by the USC Clinical Investigations Committee (CIC), the USC Clinical Trials Unit (CTU), NIH cooperative groups, NIH study sections, sponsor review committees, and regulatory agencies such as the Food and Drug Administration). Peer reviews provide assurance that experts have evaluated the study and found it meritorious. At HSC, for protocols that have not undergone peer/scientific review, additional reviewers with knowledge in the relevant discipline may be assigned to provide confidence in the scientific merit of the study. This process assures that in addition to all other review criteria scientific merit is properly addressed.
Primary and Secondary Reviewer Responsibilities
The primary reviewer should be knowledgeable about the medical or social-behavioral issues relevant to the protocol. The primary reviewer performs a detailed review of the protocol in order to ensure that the study is appropriately designed to protect subjects and to achieve the stated goals of the project.
All reviewers are asked to upload a written review in iStar. In their written comments, reviewers identify human subjects protection concerns, explain the basis for raising those concerns, request modification to study documents, and ask for clarification or additional information. All assigned reviewers attend the IRB meeting and present their analysis to the Full Board committee. If a reviewer is unable to attend the meeting, another assigned reviewer, or the IRB Chair will present the review to the committee. Even if written comments are provided by the assigned reviewers, the board might choose to defer discussion of a protocol until a time when the assigned reviewer can attend the meeting and present concerns in person.
Use of Consultant Reviewers
If the IRB Chair/Director determines that the IRB lacks the expertise necessary to review a particular study, the IRB will seek the services of an external consultant reviewer. An expert will be identified and invited to review the study as a consultant. The consultant will be required to disclose any possible conflict of interest to the IRB using the same criteria applied to investigators as outlined in Section 12.6 – Investigator Conflict of Interest. Once it is confirmed that there are no actual or perceived conflicts of interest, a copy of the complete study submission and any reviews posted by the other reviewers will be sent to the consultant. The consultant will provide written comments to the IRB and may be invited to attend the meeting to discuss the protocol. The consultant cannot vote.
Meeting Materials – Full Board
The IRB staff electronically distributes all meeting materials to IRB members or their alternates through iStar. To ensure adequate time for review, the meeting agenda, study documents, and minutes to be approved by the board are sent to members approximately seven days before the meeting. Meeting materials available to IRB members for new study submissions are listed below.
- iStar study application
- Previous correspondence from study team and IRB
- Study protocol
- Grant application (including budget)
- Sponsor’s sample informed consent documents
- Drug and device brochures
- Informed consent documents
- Child assent forms
- Surveys, questionnaires, and other instruments
- Recruitment materials
- HIPAA authorization forms and other documents required for medical research
A list of meeting materials for Continuing Review, amendments, and reportable event submissions are found in their respective sections in Chapter 8 – IRB Considerations after Initial Approval.
Projects Needing Verification from Sources Other than the Investigator
The IRB may determine that verification of required changes as well as study conduct need to be provided by sources other than the investigator. The IRB determines the appropriate sources and makes that part of the contingencies for approval. The criteria used by the IRB to make these determinations could include some or all of the following:
- Complex projects involving increased risk to subjects
- Projects conducted by investigators who previously have failed to comply with the requirements of the Health and Human Services (HHS) regulations or the requirements or determinations of the IRB, and
- Projects where concern about possible material changes occurring without IRB approval have been raised based upon information provided in continuing review reports or from other sources
Other approvals may be necessary before a study can begin, depending on the type of funding and the type of study. Funding and contract agreements are negotiated through USC Department of Contracts and Grants and/or the Clinical Trials Office. The IRB application will inform the reviewer and/or investigator if additional approvals must be obtained. The ancillary approvals are described below.
Department of Contracts and Grants
All research funds received from federal, state, and local government and/or private/foundations must be processed by the Department of Contracts and Grants (DCG). The DCG:
- Serves as “gatekeeper” for acceptance, oversight and disbursement, and fulfilling government and university requirement
- Provides training and assistance to faculty and research administration staff
- Assists with proposal development, review, approval and submission
- Negotiates and accepts awards on behalf of the University
- Offers post-award administrative guidance
- Maintains the Sponsored Projects Data Information System (DCG Database)
Provides support to University offices and committees in matters related to research policy and guidelines
Clinical Trials Office (Industry-funded)
The Clinical Trials Office (CTO) provides budget development and contract negotiation and execution for industry-sponsored research.
Medicare Coverage Analysis (MCA) and Consistency Review
CTO staff prepares the Medicare Coverage Analysis (MCA) for all clinical trials regardless of the funding source or Medicare eligibility. CTO verifies that the terms of “qualifying trials” are met before study costs are allocated. The MCA is used to identify and differentiate between costs that are study-related and those that are routine care. Routine care costs are billed to Medicare, another insurer, or the subject.
The IRB staff works closely with CTO to ensure that language in the informed consent document and iStar application is consistent with the sponsor contract or Clinical Trial Agreement. CTO staff will modify and approve the language in the Financial Obligation and Compensation section of the iStar application as needed. This is accomplished using the “Review Consistency” activity.
If the investigator has addressed all the IRB contingencies before the CTO review is final, the IRB will approve the study but will not release the informed consent documents. The investigator cannot begin recruitment and enrollment until the CTO review is completed, the IRB confirms that the cost, injury, and compensation sections of the consent documents match the CTO language, and the IRB uploads the stamped consent documents in iStar. The IRB will notify investigators when the approved consent documents are uploaded, and enrollment can begin.
Contract and Funding Agreements
At USC, the Clinical Trials Office and the Department of Contracts and Grants are responsible for funding agreements. All institutional contract and funding agreements must meet established standards, including:
- A written agreement addressing medical care for research participants with a research-related injury, when appropriate
- A written agreement stating that the sponsor promptly reports to USC findings that could affect the safety of participants or influence the conduct of the study (for studies in which sponsors conduct site monitoring visits or conduct monitoring activities remotely)
- A written agreement that addresses provisions for monitoring the data to ensure the safety of participants and for providing data and safety monitoring reports to USC, when the sponsor has the responsibility to conduct data and safety monitoring
- A written agreement, before initiating research, that addresses plans for disseminating findings from the research and the roles that researchers and sponsors will play in the publication or disclosure of results
A written agreement that the researcher or USC will be notified of the results in order to consider informing participants, when participant safety could be directly affected by study results after the study has ended
Ancillary Committee Reviews
Depending on the study, additional ancillary committee review and approval may be necessary before the study can begin. Certain required approvals may be identified and requested during IRB submission or some approvals may be required after IRB submission depending on the study. Ancillary committees include:
- Institutional Biosafety Committee (IBC)
- Radiation Safety Committee (RSC)
- Stem Cell Research Oversight Committee (SCRO)
- Conflict of Interest in Research Committee (CIRC)
- Investigational Drug Pharmacy Services
- Pathology and Laboratory Services
- Clinical Trials Unit (CTU)
- Cancer Center Clinical Investigations Committee (CIC)
Full Board Review
At a convened meeting, after the assigned reviewers present their analyses of the study, the discussion is opened to all members. During the discussion, other members note omissions, raise and/or comment on issues, request clarifications, and make suggestions to improve the readability of consent and recruitment material. When all members have the opportunity to voice their concerns and no further discussion is necessary, the board votes upon the study and makes one of the following determinations:
If the board determines that the study as written provides adequate protection of human subjects, the board will approve the study with no further changes.
Approve with Contingencies
Contingencies verified by designated reviewer
If the board finds that the application is “approvable” with modifications, clarifications, or verifications, the board will approve the study with contingencies that can be verified by a designated reviewer. The IRB may require the following as conditions of approval:
- confirmation of specific assumptions or understandings on the part of the IRB regarding how the research will be conducted;
- submission of additional documentation;
- precise language changes to protocol or informed consent documents; or
- substantive changes to protocol or informed consent documents along with clearly stated parameters that the changes must satisfy.
The IRB may designate the verification of satisfied contingencies to the IRB Chair or an IRB member, without additional review by the Full Board. This process does not constitute an expedited review.
Contingencies Verified by Staff
If changes proposed are administrative/editorial in nature, not part of the approval criteria than no additional IRB review is needed, and the changes can be reviewed as part of the verification process.
If the board has serious concerns about the study, and/or requires significant modifications directly relevant to the criteria for regulatory determinations under 45 CFR 46.111 and/or 21 CFR 56.111, the board must defer a vote on the approval of the study. The subsequent response to request for significant modifications may not be reviewed using expedited procedures and must be reviewed by the Full Board. Examples of significant modifications include more than minor changes to the risks, research design and methodology, statistical analyses, data safety monitoring plan, provisions for protecting human subjects’ safety and privacy, and informed consent document(s).
If the board is unable to initiate a discussion of a study due to a lack of time, loss of quorum, or the absence of a reviewer, the board will table the discussion of the study for review at a subsequent meeting.
If the application describes research activities that may pose significant concerns for human subject safety with minimal prospect of benefit, or the risk/benefit ratio is deemed to be unfavorable, the board may disapprove the study.
An IRB member makes a motion for one of the above options; if another member of the IRB seconds the motion, the motion is voted upon. A majority of the members present at the meeting must vote in favor of the motion for passage [45 CFR 46.108(b) and 21 CFR 56.108(c)]. Discussion and/or deliberations of each study on the meeting agenda continues until one of the above motions is passed.
Expedited and Exempt Review
The IRB designated reviewer can make one of the following determinations:
- Determine that the study as written provides adequate protection of human subjects and approves the study (with no further changes). The IRB will approve a study only after determining that the proposed application contains sufficient information to address the criteria for IRB approval cited at 45 CFR 46.111 and 21 CFR 56.111.
- If the reviewer has serious concerns about the study, and/or requires significant modifications directly relevant to the criteria for regulatory determinations under 45 CFR 46.111 and/or 21 CFR 56.111, the expedited reviewer can refer the study for Full Board review.
- Find that the application is “approvable” after modifications, clarifications, or verifications and designate a reviewer (same reviewer, IRB Chair, another IRB reviewer, or IRB administrator) to verify that contingencies have been satisfied.
Review of Response to Contingencies
When a study is approved with contingencies, the IRB designates a reviewer (same reviewer, IRB Chair, another IRB reviewer, or IRB administrator) to verify that contingencies have been satisfied.
- If the designated reviewer determines that the investigator has satisfied all conditions of approval, further IRB review is not necessary.
- If the reviewer determines that the investigator failed to adequately address the modifications requested by the IRB, the investigator’s response may be returned to another member reviewer or to a Full Board meeting. The reviewer may request additional correspondence identifying outstanding concerns to be sent to the investigator by IRB staff.
- If the reviewer determines that the initial response and/or secondary correspondence from the investigator is inadequate, unacceptable, or raises new concerns, the study will be forwarded to the full IRB for further adjudication at the next possible IRB meeting.
Additionally, the following applies when changes to research are proposed after the IRB has approved the research with contingencies:
- If changes proposed are administrative/editorial in nature, no additional IRB review is needed, and the changes can be reviewed as part of the verification process.
- If additional changes/procedures, which are listed in the expedited review categories under 45CFR 46.110, are proposed by the PI or designated reviewer, those changes may be reviewed by the IRB Chair or designated reviewer through an expedited review procedure.
- If changes are more than minor, increase risks to subjects, and/or impact any of the approval criteria under 45 CFR 46.111, those changes would require review by the full IRB committee.
This review process is applicable to review of response to contingencies after initial study submission, amendments, continuing review and reportable events.
After each IRB meeting (or review by designated reviewer), the IRB staff forwards correspondence to investigators whose protocols were reviewed, notifying them of the action/status of their applications. The nature of the correspondence and the process by which an investigator’s response is reviewed vary according to the decision made for the study.
- When the board (or reviewer) determines that the study as written provides adequate protections, the correspondence indicates the study is approved (with no further changes).
- When the board (or reviewer) finds that the application is “approvable” after modifications, clarifications, or verifications, the correspondence indicates the study is approved with contingencies.
- When a study is approved with contingencies, the IRB staff composes correspondence describing reviewers’ comments and concerns and forwards it to the investigator. The investigator’s response to the correspondence is then reviewed by the Chair or designee. Correspondence indicates when the IRB or reviewer previously agreed that a response may be evaluated by a designated reviewer.
- When the IRB or reviewer has serious concerns about a study, or if significant modifications are required to ensure protection of human subjects, the correspondence indicates that the IRB will defer approval of the study until additional information is obtained from the investigator.
- For Full Board studies, when the board is unable to initiate a discussion of a study due to a lack of time or the absence of a reviewer, the correspondence indicates the board will table the discussion of the study for review at a subsequent meeting.
- When the application describes research activities that may pose significant concerns for human subject safety with minimal prospect of benefit, or the risk/benefit ratio is deemed to be unfavorable, the correspondence indicates the IRB’s decision to disapprove the study. Investigator will have the opportunity to respond to the board in person or in writing [45 CFR 46.109(d) and 21 CFR 56.109(e)].
IRB correspondence includes all the information required by federal regulations and/or guidance. Generally, IRB correspondence for Full Board review studies is approved by the Chair before it is sent to investigators.
IRB correspondence with IRB determinations and the IRB’s action will be sent to the investigator [45 CFR 46.109(d) and 21 CFR 56.109(e)]. When responding to the IRB’s determinations or requests, the investigator may disagree with the board or reviewer, and provide written justification in support of their viewpoint. The IRB will then review the investigator’s justification and make a determination. It should be noted, however, that the IRB has the final authority to approve or disapprove the research.
During the IRB review process, all requests for modifications or further clarifications from the IRB are documented in a letter and sent to the investigator by IRB staff via iStar. The investigator’s response to the IRB correspondence is evaluated in accordance with the requirement set forth during the initial review (reviewed by the Full Board, reviewed by an expedited reviewer, or verified by an IRB staff member). All correspondence between the IRB and investigators is recorded and stored under the history tab in the iStar application.
If the investigator believes requirements imposed by the IRB are unduly restrictive of the proposed research, the investigator can contest the requirements to the IRB. The investigator can outline the reasons why the proposed research procedures are already in compliance with USC policy and the applicable federal regulations and request that the IRB reconsider the requirement. If the IRB rejects the appeal, the investigator must comply with the IRB’s contingencies or the research will not be approved. No other entities or officials at USC may override the IRB’s decision to disapprove a study.
Other institutional entities or officials may determine that a study approved by the IRB cannot be conducted. Among the reasons for disapproval are issues of inadequate resources or university sensitivities.
IRB Meeting Schedule for Biomedical Study Review
BioIRB 1 meets the first and third Thursday of each month. BioIRB 2 meets the second and fourth Thursday of each month. BioIRB 3 meets on the first and third Tuesday of each month. A calendar for submission and review dates is available on the HRPP website.
IRB Meeting Schedule for Social Behavioral Study Review
The IRB reviews social and behavioral studies monthly. A calendar for submission and review cut-off dates is available on the HRPP website.
In addition to the IRB submissions described earlier in this chapter, there are other IRB submissions applicable to human subjects research. These IRB submissions include Continuing Review, Amendments, Reportable Events, and Reports. These submissions are not discussed further in this chapter as they are described in Chapter 6 – Types of IRB Submissions and discussed as part of the IRB submission process in Chapter 9 – IRB Considerations after Initial Approval.